Cancer incidence in the U.S. Air Force: 1989-2002.
ABSTRACT Cancer incidence in U.S. Air Force active duty (AFAD) personnel is unknown. Defining the epidemiology may support more effective prevention and clinical services.
Standardized incidence ratios (SIRs) for invasive cancer in AFAD personnel during 1989-2002 were determined using U.S. national incidence rates as the reference. SIRs were adjusted for age and race. Cutaneous squamous and basal cell carcinomas (CAs) were excluded.
There were 2750 cases: 1986 in men and 764 in women. The all-cancers SIRs were for men, 0.50 (95% CI: 0.48-0.53), and for women, 0.96 (95% CI: 0.89-1.03). Among men, the 10 most frequent cancers (77.6% of total) were, in descending order: melanoma; testicular CA; prostate CA; non-Hodgkin lymphoma; follicular/papillary thyroid CA; Hodgkin's Disease; colorectal CA; brain neuroepithelial CA; and (tied) bladder CA and oral squamous cell CA. Among women, the 10 most frequent cancers (88.1% of total) were, in descending order: breast CA; cervical CA; follicular/papillary thyroid CA; melanoma; Hodgkin's Disease; colorectal CA; (tied) non-Hodgkin lymphoma and ovarian epithelial CA; vulvar CA; and (tied) brain neuroepithelial CA and oral squamous cell CA. Compared with the U.S. population, cancer type-specific SIRs were significantly increased for cervical CA, prostate CA, and vulvar CA (range, 1.44-3.54). SIRs were significantly decreased for bladder CA (men), brain neuroepithelial CA, colorectal CA (men), Hodgkin's Disease (men), non-Hodgkin lymphoma, oral squamous cell CA (men), and testicular CA (range, 0.31-0.68). The remaining SIRs were not significantly different from unity.
The cancer experience of the AFAD population differs substantially from that of the U.S. population.
- SourceAvailable from: ocean.kisti.re.kr[Show abstract] [Hide abstract]
ABSTRACT: Pilots are exposed to carcinogenic substances like radiation, ozone, exhaust gas from jet engine, and electromagnetic wave, their environment can be very hazardous. I designed this study to know if there is any difference between pilots and general people in cancer incidence. I analyzed cancer cases between 1999 and 2008, and investigated their age, site, aircraft types, and sex. I compared pilot's cancer incidence with general people during same periods. Statistical analysis was performed with standardized incidence ratio (SIR). 10 cases were high performance pilots, 5 cases were low performance pilots. The average age when the diagnosis had been made was . Pilot's incidence ratio was lower than people's, the most common cancer was kidney, and there was no lung cancer. Cancer is influenced by gene and environment, each country has different patterns. The low incidence ratio in Korean pilots might be due to "healthy worker effect". I think we should perform further investigation on kidney cancer.01/2011; 19(4).
- [Show abstract] [Hide abstract]
ABSTRACT: BackgroundA cancer incidence and mortality study was conducted in response to health concerns raised by workers from F-111 aircraft deseal/reseal fuel tank maintenance programs, to determine whether personnel exposed to deseal/reseal had an excess of cancers and mortality.Methods Number of deaths and cancers for individuals involved in F-111 DSRS activities were matched against two Air Force comparison groups. Analyses were weighted to adjust for differences in age, exposure period and rank.ResultsEight hundred seventy-three exposed, 7,577 comparison group one, and 9,408 comparison group two individuals were matched against death and cancer data, with 431 cancers and 431 deaths. Cancer incidence was higher in the exposed group, with marginally significant increases of 40–50% (cancer incidence rate ratio range 1.45–1.62). Exposed group mortality was significantly lower than both comparison groups, likely due to survivor bias in the exposed group (mortality rate ratio range 0.33–0.44).Conclusions On the balance of probabilities, there is an increased risk of cancer associated with participation in F-111 deseal/reseal activities. Am. J. Ind. Med. 51:16–23, 2008. © 2007 Wiley-Liss, Inc.American Journal of Industrial Medicine 01/2008; 51(1):16 - 23. DOI:10.1002/ajim.20540 · 1.59 Impact Factor